Search results for "TYPE 2 DIABETES"

showing 10 items of 659 documents

Diabetes-related nutrition knowledge and dietary intake among adults with type 2 diabetes.

2015

Nutrition knowledge and skills enable individuals with type 2 diabetes (T2DM) to make food choices that optimise metabolic self-management and quality of life. The present study examined the relationship between nutrition knowledge and skills, and nutrient intake in T2DM. A cross-sectional analysis of diabetes-related nutrition knowledge and nutrient intake was conducted in 124 T2DM individuals managed in usual care (64 % male, age 57·4 (sd 5·6) years, BMI 32·5 (sd 5·8) kg/m2), using the Audit of Diabetes Knowledge (ADKnowl) questionnaire and a 4 d food diary. Data on sociodemographic characteristics, food label use and weight management were also collected. The average ADKnowl dietary subs…

Blood GlucoseMaleHealth Knowledge Attitudes PracticeSettore MED/09 - Medicina InternaMEDLINEMedicine (miscellaneous)Health knowledgeType 2 diabetesBody Mass IndexNutrition knowledgeNutrientQuality of lifePatient Education as TopicFood LabelingSurveys and QuestionnairesDiabetes mellitusEnvironmental healthWeight managementFood choiceVegetablesNutrition and DieteticmedicineHumansNutritional Physiological PhenomenaGlycated HemoglobinNutrition and Dieteticsbusiness.industryMedicine (all)Dietary intakeBody WeightMiddle Agedmedicine.diseaseLipidsDiet RecordsDietDiabetes Mellitus Type 2Glycemic IndexQuality of LifeNutritional Physiological PhenomenaFemaleWaist CircumferencebusinessDiabetes Mellitus Type 2; Female; Humans; Male; Diet; Health Knowledge Attitudes Practice; Nutritional Physiological Phenomena; Medicine (miscellaneous); Nutrition and Dietetics; Medicine (all)HumanThe British journal of nutrition
researchProduct

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 D…

2018

This study evaluates the relation of a Mediterranean dietary pattern and its individual components with the cardiovascular risk factors profile, plasma glucose and body mass index (BMI) in people with type 2 diabetes. We studied 2568 participants at 57 diabetes clinics. Diet was assessed with the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, adherence to the Mediterranean diet was evaluated with the relative Mediterranean diet score (rMED). A high compared to a low score was associated with a better quality of diet and a greater adherence to the nutritional recommendations for diabetes. However, even in the group achieving a high score, only a small prop…

Blood GlucoseMaleMediterranean diet; cardiovascular risk; diabetes; glucose control; plasma lipids; relative Mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Healthy; Diet Mediterranean; Feeding BehaviorGlycated Hemoglobin AMediterranean dietRecommended Dietary AllowanceCross-sectional studyHealthy DietSaturated fatBlood PressureType 2 diabetes030204 cardiovascular system & hematologyMediterraneanDiet MediterraneanDiabeteRecommended Dietary AllowancesSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsCardiovascular Disease030212 general & internal medicineNutrition and DieteticsdiabetesLipidMiddle AgedLipidsEuropean Prospective Investigation into Cancer and NutritionCardiovascular DiseasesFemaleDiet Healthylcsh:Nutrition. Foods and food supplyNutritive ValueType 2Humancardiovascular riskCardiovascular risk; Diabetes; Glucose control; Mediterranean diet; Plasma lipids; Relative mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Mediterranean; Feeding Behavior; Healthy Diet; Food Science; Nutrition and DieteticsPlasma lipidlcsh:TX341-641Article03 medical and health sciencesEnvironmental healthDiabetes mellitusMediterranean dietplasma lipidsmedicineDiabetes MellitusHumansProtective FactorAgedCross-Sectional StudieGlycated Hemoglobinglucose controlHealthybusiness.industryRisk FactorBiomarkerFeeding Behaviorrelative Mediterranean diet scoreProtective Factorsmedicine.diseaseDietCross-Sectional StudieschemistryDiabetes Mellitus Type 2Patient ComplianceGlycated hemoglobinbusinessBody mass indexBiomarkersFood Science
researchProduct

The role of morbid obesity in the promotion of metabolic disruptions and non-alcoholic steatohepatitis by Helicobacter Pylori

2016

Background Helicobacter pylory (HP) infection has been associated to an increased rate of type 2 diabetes (T2D) and liver disease through its effect on insulin resistance and systemic inflammation. However, results are inconstant and no studies exist in morbidly obese patients, in which both insulin resistance and inflammation coexist. Material and methods Cross-sectional study to evaluate the relationship between HP infection and alterations in carbohydrate metabolism, lipid profile, inflammation markers, and liver disease in patients awaiting for bariatric surgery. HP infection was histologically assessed in gastric antrum biopsy from 416 subjects. Liver biopsy was also available in 93 su…

Blood GlucoseMalePhysiologyBiopsylcsh:MedicineType 2 diabetesPathology and Laboratory MedicineBiochemistryGastroenterologyLiver diseaseEndocrinology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceImmune ResponseMultidisciplinarymedicine.diagnostic_testLiver DiseasesFatty liverMiddle AgedObesity MorbidPhysiological ParametersLiver biopsyCarbohydrate MetabolismFemale030211 gastroenterology & hepatologyResearch ArticleAdultmedicine.medical_specialtyEndocrine DisordersImmunologySurgical and Invasive Medical ProceduresGastroenterology and HepatologyHelicobacter Infections03 medical and health sciencesSigns and SymptomsInsulin resistanceDiagnostic MedicineInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumansObesityInflammationHelicobacter pyloriEndocrine Physiologybusiness.industryBody Weightlcsh:RBiology and Life Sciencesmedicine.diseaseImpaired fasting glucoseMorbid ObesityFatty LiverCross-Sectional StudiesMetabolismEndocrinologyDiabetes Mellitus Type 2Metabolic Disorderslcsh:QInsulin ResistanceSteatohepatitisbusiness
researchProduct

Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism

2018

Background: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events. The ingestion of high-glycemic index (GI) diets, specially sweetened beverage consumption, has been associated with the development of T2DM and CV disease. Objective: We investigated the effects of the intake of a sweetened beverage, obtained from natural carbohydrates containing pinitol (PEB) compared to a sucrose-enriched beverage (SEB) in the context of impaired glucose tolerance (IGT) and diabetes. Methods: The study was divided in three different phases: (1) a discovery phase where the plasma proteomic profile was investigated by 2-DE (two-dimensional electrophoresis) follow…

Blood GlucoseMaleProteomicstype 2 diabetes mellitusmedicine.medical_treatmentType 2 diabetes030204 cardiovascular system & hematologyBody Mass IndexImpaired glucose tolerance0302 clinical medicineInsulinInsulin-Like Growth Factor INutrition and DieteticsbiologyChemistryComplement C4aFabaceaeMiddle AgedHealthy Volunteerslcsh:Nutrition. Foods and food supplyNutritive SweetenersAdultmedicine.medical_specialtyAdolescentsweetenerBlood sugarlcsh:TX341-641030209 endocrinology & metabolismCarbohydrate metabolismArticleDiabetes Mellitus ExperimentalBeveragesinsulin-like growth factor03 medical and health sciencesYoung AdultInsulin resistanceDouble-Blind MethodInternal medicineDiabetes mellitusGlucose IntolerancemedicineAnimalsHumansC4A complementAgedGlycated HemoglobinPlant ExtractsInsulinOverweightmedicine.diseaseRatsRats Zuckerimpaired glucose tolerance; type 2 diabetes mellitus; sweetener; insulin-like growth factor; C4A complementDisease Models AnimalEndocrinologyimpaired glucose toleranceDiabetes Mellitus Type 2biology.proteinGLUT2InositolFood ScienceNutrients; Volume 10; Issue 3; Pages: 271
researchProduct

Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the …

2019

OBJECTIVE: To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS: From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical a…

Blood GlucoseMaleResearch designmedicine.medical_specialtyRandomizationEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismSubgroup analysisType 2 diabetesDiet Mediterraneanlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicinePropensity ScoreDiet Fat-RestrictedOlive OilDieta -- Mediterrània Regió de laAgedProportional Hazards ModelsAdvanced and Specialized NursingDiabetisbusiness.industryHazard ratioClinical Care/Education/Nutrition/Psychosocial ResearchMiddle Agedmedicine.diseaseTreatment OutcomeDiabetes Mellitus Type 2Multivariate AnalysisPropensity score matchingFemale0405business
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct

Timing of Exercise Affects Glycemic Control in Type 2 Diabetes Patients Treated with Metformin

2018

Objective. The purpose of the study was to examine the acute effects of the timing of exercise on the glycemic control during and after exercise in T2D. Methods. This study included 26 T2D patients (14 women and 12 men) who were treated with metformin. All patients were tested on four occasions: metformin administration alone (Metf), high-intensity interval training (HIIT) performed at 30 minutes (EX30), 60 minutes (EX60), and 90 minutes (EX90) postbreakfast, respectively. Glucose, insulin, and superoxide dismutase (SOD) activity were examined. Results. Glucose decreased significantly after the exercise in EX30, EX60, and EX90. Compared with Metf, the decline in glucose immediately after th…

Blood GlucoseMaleTime Factorsendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentmetformiiniajoitus (suunnittelu)Type 2 diabetes030204 cardiovascular system & hematologyHigh-Intensity Interval TrainingGastroenterologylcsh:Diseases of the endocrine glands. Clinical endocrinologyInterval training0302 clinical medicineEndocrinologyInsulinta315type 2 diabetes patientskuntoliikuntata3141Middle Agedtiming of exerciseMetforminFemaleHigh-intensity interval trainingmedicine.drugAdultmedicine.medical_specialtyArticle Subject030209 endocrinology & metabolism03 medical and health sciencesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsExercise physiologyExerciseGlycemiclcsh:RC648-665business.industrySuperoxide DismutaseInsulinmedicine.diseaseDiabetes Mellitus Type 2verensokeriClinical Studyglycemic controlbusinessmetforminaikuistyypin diabetesJournal of Diabetes Research
researchProduct

Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study.

2019

Key Points Question Is birth weight associated with type 2 diabetes and glycemic traits? Findings This mendelian randomization study found that a 1-SD decrease in birth weight due to the genetic risk score was associated with a higher risk of type 2 diabetes among European and East Asian populations. In addition, a 1-SD decrease in birth weight was associated with a 0.189-SD increase in fasting glucose concentration, but not with fasting insulin, 2-hour glucose, or hemoglobin A1c level. Meaning A genetic predisposition to lower birth weight was associated with an increased risk of type 2 diabetes and increased fasting glucose, suggesting potential mechanisms through which perturbation of th…

Blood GlucoseMaleType 2 diabetes0302 clinical medicineOdds RatioBirth WeightInsulin030212 general & internal medicineOriginal Investigation0303 health sciencesAsia EasternMendelian Randomization AnalysisGeneral MedicineMiddle Aged16. Peace & justice3. Good healthOnline OnlyDiabetes and EndocrinologyFemaletype 2 diabetesAdultmedicine.medical_specialtyDiabetes riskAdolescentBirth weightPolymorphism Single NucleotideWhite People03 medical and health sciencesYoung AdultSDG 3 - Good Health and Well-beingAsian PeopleDiabetes mellitusInternal medicineMendelian randomizationmedicineHumans030304 developmental biologyGlycemicAgedGlycated Hemoglobinbusiness.industryResearchInfant Newbornbirth weightGenetic VariationOdds ratioMendelian Randomization Analysismedicine.diseaseDiabetes Mellitus Type 2mendelian randomization studybusinessJAMA network open
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct